Strong antitumor synergy between DNA crosslinking and HSP90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells

All current regimens for treating ovarian cancer center around carboplatin as standard first line. The HSP90 inhibitor ganetespib is currently being assessed in advanced clinical oncology trials. Thus, we tested the combined effects of ganetespib and carboplatin on a panel of 15 human ovarian cancer...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cell Death Differ
Главные авторы: Kramer, Daniela, Stark, Nadine, Schulz-Heddergott, Ramona, Erytch, Norman, Edmunds, Shelley, Roßmann, Laura, Bastians, Holger, Concin, Nicole, Moll, Ute M, Dobbelstein, Matthias
Формат: Artigo
Язык:Inglês
Опубликовано: Nature Publishing Group 2017
Предметы:
Original Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5299713/
https://ncbi.nlm.nih.gov/pubmed/27834954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/cdd.2016.124
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы